

WEST**Freeform Search****Database:**

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term:

15 and L6

Display: **Documents in Display Format:** **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History**DATE:** Tuesday, August 19, 2003 [Printable Copy](#) [Create Case](#)**Set Name Query**

side by side

Hit Count Set Name

result set

DB=USPT,PGPB; PLUR=YES; OP=AND

<u>L7</u>	15 and L6	16	<u>L7</u>
<u>L6</u>	infus\$ near6 artery	1296	<u>L6</u>
<u>L5</u>	13 and L4	675	<u>L5</u>
<u>L4</u>	(coronary or sinus) adj (artery or blood adj vessel)	15567	<u>L4</u>
<u>L3</u>	11 and L2	1747	<u>L3</u>
<u>L2</u>	(cardiovascular or cardiac or heart) near3 (disease or disorder or defect)	28230	<u>L2</u>
<u>L1</u>	adeno-associated adj virus or aav	6380	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 16 of 16 returned.**

-
- ☐ 1. [20030148968](#). 03 May 01. 07 Aug 03. Techniques and compositions for treating cardiovascular disease by in vivo gene delivery. Hammond, H. Kirk, et al. 514/44; 604/500 A61K048/00 A61M031/00.
-
- ☐ 2. [20030147862](#). 16 Oct 00. 07 Aug 03. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Buschmann, Ivo R., et al. 424/93.21; 514/12 514/44 A61K048/00 A61K038/18.
-
- ☐ 3. [20030100889](#). 03 Jul 02. 29 May 03. Method of administration of a gene of interest to a vascular tissue. Duverger, Nicolas, et al. 604/522; 435/320.1 604/509 A61M031/00.
-
- ☐ 4. [20030096747](#). 23 May 02. 22 May 03. Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder. Lue, Tom F., et al. 514/12; 424/93.2 514/44 A61K048/00 A61K038/18.
-
- ☐ 5. [20030012768](#). 11 Jul 01. 16 Jan 03. Connective tissue growth factor-2. Li, Haodong, et al. 424/93.2; 435/456 514/44 A61K048/00 C12N015/861.
-
- ☐ 6. [20020187132](#). 30 Apr 01. 12 Dec 02. Cardiac gene transfer. McGregor, Christopher G.A., et al. 424/93.21; 435/455 A61K048/00 C12N015/85.
-
- ☐ 7. [20020176847](#). 08 Mar 02. 28 Nov 02. Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling. Rajavashisth, Tripathi. 424/93.2; 435/456 514/44 A61K048/00 C12N015/86.
-
- ☐ 8. [20020160951](#). 19 Jul 01. 31 Oct 02. Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder. Lue, Tom F., et al. 514/12; 514/44 A61K048/00 A61K038/18.
-
- ☐ 9. [20020155101](#). 06 Sep 01. 24 Oct 02. Cardiac arrhythmia treatment methods. Donahue, J. Kevin, et al. 424/93.21; 435/6 514/44 C12Q001/68 A61K048/00.
-
- ☐ 10. [20020131959](#). 14 Mar 01. 19 Sep 02. Means and methods for the modulation of arteriogenesis. Buschmann, Ivo, et al. 424/93.21; 424/85.1 424/85.2 514/2 514/44 A61K048/00 A61K038/18 A61K038/19 A61K038/20.
-
- ☐ 11. [RE37933](#). 21 Dec 00; 10 Dec 02. Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis. Branellec; Didier, et al. 424/93.2; 435/320.1 435/325 435/375 435/456 514/44 536/23.5. A61K035/76 A61K048/00 C12N015/86 C12N015/63.
-
- ☐ 12. [6271211](#). 21 Mar 00; 07 Aug 01. Gene therapy for regulating penile smooth muscle tone. Christ; George J., et al. 514/44; 435/320.1 435/325 435/455 530/350 536/23.1 536/23.5. A01N043/04 A61K031/70 C12N015/00 C12N015/09 C12N015/63.
-
- ☐ 13. [6239117](#). 21 Mar 00; 29 May 01. Gene therapy for regulating bladder smooth muscle tone.

Christ; George-J., et al. 514/44; 435/320.1 435/325 435/455 530/350 536/23.1 536/23.5 800/8.
A01N043/04 A61K031/70.

☒ 14. 6174871. 10 Aug 98; 16 Jan 01. Gene therapies for enhancing cardiac function. Hammond; H. Kirk, et al. 514/44; 424/93.6 435/320.1 536/23.5. A01N043/04 A01N063/00 A61K031/70 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.

☒ 15. 5858990. 04 Mar 97; 12 Jan 99. Fas ligand compositions for treatment of proliferative disorders. Walsh; Kenneth. 514/44; 435/320.1 435/375 435/377 435/6 435/69.1. A61K048/00 C12N015/11.

☐ 16. 5851521. 30 Sep 96; 22 Dec 98. Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis. Branellec; Didier, et al. 424/93.2; 435/320.1 435/325 435/375 435/456 514/44 536/23.5. A61K035/76 A61K048/00 C12N015/86 C12N015/63.

Generate Collection

Print

Terms	Documents
15 and L6	16

[Previous Page](#)

[Next Page](#)

=> d his

(FILE 'HOME' ENTERED AT 13:52:11 ON 19 AUG 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 13:52:41 ON 19 AUG 2003

L1 9353 S ADENO-ASSOCIATED(W)VIRUS OR AAV
L2 624387 S (CARDIOVASCULAR OR CARDIAC OR HEART) (3A) (DISEASE OR DEFECT OR
L3 187 S L1 AND L2
L4 94404 S GENE(W) THERAPY
L5 4220 S L1 AND L4
L6 295912 S (CORONARY OR SINUS) (3A) ARTERY
L7 39 S L5 AND L6
L8 33 DUP REM L7 (6 DUPLICATES REMOVED)
L9 19 S L3 AND L8
L10 19 DUP REM L9 (0 DUPLICATES REMOVED)
L11 13176 S INFUS?(6A) ARTERY
L12 5 S L3 AND L11
L13 3 DUP REM L12 (2 DUPLICATES REMOVED)

=> d au ti so ab 1-19 19

L9 ANSWER 1 OF 19 MEDLINE on STN
AU Asfour B; Baba H A; Scheld H H; Hruban R H; Hammel D; Byrne B J
TI Uniform long-term gene expression using **adeno-associated virus (AAV)** by ex vivo recirculation in rat-cardiac isografts.
SO THORACIC AND CARDIOVASCULAR SURGEON, (2002 Dec) 50 (6) 347-50.
Journal code: 7903387. ISSN: 0171-6425.
AB BACKGROUND: **Gene therapy in cardiovascular disease** promises to be of great impact. The ideal vector for the therapeutic gene transfection remains to be determined. The aim of the present study was to investigate the efficacy of gene transfer using **adeno-associated virus** vectors carrying the lacZ-reporter gene (**AAV-lacZ**) in a previously described coronary recirculation model. METHODS: Beating Lewis rat hearts perfused with oxygenated Krebs-Henseleit solution were harvested, after which an atrial septal defect (ASD) was created. All vessels were tied, and **AAV-lacZ** was injected into the aortic root. The solution was recirculated through the ASD to the left side of the heart and pumped back to the **coronary arteries** by the left ventricle. Incubation was allowed for 20 min at 15 degrees C, and the hearts were subsequently transplanted heterotopically in syngeneic rats. Three increasing doses (109, 1,010, 1,011 e. u.) of **AAV-lacZ** virus vectors were used to study the rate of gene transfer. All hearts were harvested after 7-60 days and evaluated histologically for expression of the lacZ-gene. RESULTS: Dose-dependent gene transfer was observed. Even after 60 days, there was no obvious decline in gene expression. CONCLUSION: **Adeno-associated virus** vectors offer effective and uniform gene transfer in the myocardium after transc coronary injection and recirculation. Due to the lack of immune response previously described, no decrease in gene expression can be observed up to 60 days after injection.

L9 ANSWER 2 OF 19 MEDLINE on STN
AU Kaplitt M G; Xiao X; Samulski R J; Li J; Ojamaa K; Klein I L; Makimura H; Kaplitt M J; Strumpf R K; Diethrich E B
TI Long-term gene transfer in porcine myocardium after coronary infusion of an **adeno-associated virus** vector.
SO ANNALS OF THORACIC SURGERY, (1996 Dec) 62 (6) 1669-76.
Journal code: 15030100R. ISSN: 0003-4975.
AB BACKGROUND: Viral vector-mediated gene transfer into the heart represents a potentially powerful tool for studying both cardiac physiology as well

as **gene therapy of cardiac disease**

We report here the use of a defective viral vector, which expresses no viral gene products, for gene transfer into the mammalian heart. Previous studies have used recombinant viral vectors, which retained viral genes and yielded mostly short-term expression, often with significant inflammation. **METHODS:** An **adeno-associated virus** vector was used that contains no viral genes and is completely free of contaminating helper viruses. The **adeno-associated virus** vector was applied to rat hearts by direct intramuscular injection; **adeno-associated virus** was also infused into pig hearts in vivo via percutaneous intraarterial infusion into the coronary vasculature using routine catheterization techniques. **RESULTS:** Gene transfer into rat heart yielded no apparent inflammation, and expression was observed for at least 2 months after injection. Infusion into pig circumflex **coronary arteries** resulted in successful transfer and expression of the reporter gene in cardiac myocytes without apparent toxicity or inflammation; gene expression was observed for at least 6 months after infusion. **CONCLUSIONS:** We report the use of **adeno-associated virus** vectors in the cardiovascular system as well as successful myocardial gene transfer after percutaneous **coronary artery** infusion of viral vectors in a large, clinically relevant mammalian model. These results suggest that safe and stable gene transfer can be achieved in the heart using standard outpatient cardiac catheterization techniques.

L9 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Dzau, Victor; Melo, Luis G.; Perrella, Mark A.; Agrawal, Reitu
TI Methods of treating **cardiac disorders**
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2

AB The invention features methods and compns. for treating ischemic and reperfusion related injury such as **cardiac disorders**. Cardiomyocyte cell death is prevented by administering a compn. contg. a nucleic acid encoding a human heme oxygenase-1 polypeptide or extracellular superoxide dismutase polypeptide or biol. active fragment thereof. Among the examples provided are: myocardial tissue from oxidative stress by gene HO-1 delivery via an adeno-assocd. vector, effect of HO-1 gene transfer on oxidative stress-induced lipid peroxidn. and expression of apoptosis-related proteins and inflammatory cytokines, and myocardial protective action of extracellular superoxide dismutase gene transfer.

L9 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hammond, H. Kirk
TI Techniques and compositions for treating **cardiovascular disease** by in vivo angiogenic polypeptide-encoding gene delivery
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2

AB Methods are provided for treating patients with **cardiovascular disease**, including **heart disease** and peripheral vascular disease. The preferred methods of the invention involve in vivo delivery of genes encoding angiogenic proteins or peptides to the myocardium or to peripheral ischemic tissue, by introduction of a vector contg. the gene into a blood vessel supplying the heart or into a peripheral ischemic tissue.

L9 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Wu, Kenneth K.
TI Vectors, compositions and methods for treating a vascular disorder
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

AB The present invention discloses vectors comprising a cyclooxygenase sequence, a prostaglandin synthase sequence, or both. The invention

further discloses methods of making such vectors, and compns. comprising such vectors. Methods for treating a patient afflicted with a vascular disorder by use of said vectors and compns. are also disclosed.

- L9 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hammond, H. Krik; Insel, Paul A.; Ping, Peipei; Post, Steven R.; Gao, Meihua
TI **Gene therapy** for congestive heart failure
SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 472,667.
CODEN: USXXCO
AB The present invention relates to methods and compns. for enhancing cardiac function in mammalian hearts by inserting transgenes that increase beta-adrenergic responsiveness within the myocardium. The present invention can thus be used in the treatment of **heart disease**, esp. congestive **heart failure**.
- L9 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Gao, Mei Hua
TI Dual recombinant **gene therapy** compositions and methods of use
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
AB The present invention relates to novel compns. and methods for the treatment of **cardiovascular disease**. More particularly, the invention relates to **gene therapy** compns. comprising at least two transgenes encoding angiogenic proteins or peptides. In one aspect the two transgenes are provided in a single gene delivery vector. Alternatively, the compn. comprises at least two vectors, each vector comprising a transgene encoding a different angiogenic protein or peptide. The invention also relates to methods of treating **cardiovascular disease** using the **gene therapy** compns.; kits for gene delivery; and pharmaceutical compns.
- L9 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hsu, Yen-Ming; Garber, Ellen
TI CD154 variants
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
AB Methods of decreasing (e.g., inhibiting) the expression of wild-type CD154 on the surface of a target cell and methods of treating a patient suffering from or predisposed to a CD154-mediated disease. In these methods, a nucleic acid construct that directs expression of a mutant CD154 lacking at least a portion of the tumor necrosis factor homologous domain ("TNFH") is introduced into a target cell (such as a T helper cell or a cytotoxic T cell). The expressed mutant CD154 binds to wild-type CD154 inside the cell, rendering the wild-type protein unable to reach the cell surface.
- L9 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Guo, Kun; Pagnoni, Marco F.; Clark, Kenneth L.; Ivashchenko, Yuri D.
TI Human protein kinase Akt3 and cDNAs encoding it and the use of the enzyme in treatment of hypoxia, apoptosis or necrosis
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
AB The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors contg. them and to their therapeutic uses, in particular for **gene therapy**. Expression of Akt3 inhibits cell death assocd. with hypoxia, apoptosis or necrosis.
- L9 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Yen, Frances; Erickson, Mary Ruth; Fruebis, Joachim; Bihain, Bernard
TI Methods of screening for compounds that modulate the LSR (lipolysis

stimulated receptor)-leptin interaction and their use in the prevention and treatment of obesity-related diseases

SO PCT Int. Appl., 247 pp.

CODEN: PIXXD2

AB The present invention is drawn to methods of screening for new compds. for the treatment of obesity and obesity-related diseases and disorders, as well as methods of treating obesity-related diseases and disorders, based on the discovery of the role of the leptin-LSR interaction in obesity. The lipolysis stimulated receptor (LSR) displays a high affinity for unmodified triglyceride-rich lipoproteins and is involved in the partitioning of dietary lipids among the liver, adipose tissue and muscle. Leptin and the leptin fragment described herein were found to diminish the postprandial lipemic response in dbPas/dbPa5 mice which lack the leptin OB receptor, thereby showing that leptin signaling can be independent of the OB receptor. Leptin increases the activity of LSR, binds directly to LSR, and that leptin binding leads to leptin degrdn. LSR is actually at least two receptors, one for triglyceride-rich lipoproteins, and one for leptin. The three subunits that make up LSR, .alpha., .beta., and .alpha.', actually combine in at least two ways: (1) .alpha. and .beta. together make up the LSR receptor for triglyceride-rich lipoproteins, and (2) .alpha.' is a necessary part of the LSR receptor for leptin, that may include .beta. as well. Thus, it is now clear that assays can be designed for identifying modulators or receptors/binding partners/signalling cascade members that are specific for the triglyceride-related activity of LSR or for the leptin-related activity of LSR or both. Further, the invention features the discovery of a 22 amino acid region of human leptin that modulates LSR activity in vitro and in vivo in the same way as the intact human leptin, thus allowing the use of only this crit. region in assays for modulators of the leptin-LSR interaction, and new leptin receptors and binding partners. The new leptin fragment can also be used in disease treatment since it is active in mice at a physiol.-relevant level.

L9 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN

AU Su, Hua; Lu, Ronghua; Kan, Yuet Wai

TI Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart

SO Proceedings of the National Academy of Sciences of the United States of America (2000), 97(25), 13801-13806

CODEN: PNASA6; ISSN: 0027-8424

AB Vascular endothelial growth factor (VEGF) plays important roles in physiol. and pathol. angiogenesis. Recent studies have demonstrated that direct injection of VEGF protein, plasmid DNA, or an adenoviral vector encoding the VEGF gene into ischemic myocardium or limb can induce collateral blood vessel formation and improve perfusion of the ischemic areas. However, these approaches have limitations ranging from a short-lasting effect to angioma formation. In this study, we investigated the feasibility of using adeno-assocd. viral (AAV) vectors to deliver VEGF genes to mouse myocardium. A cytomegalovirus promoter was used to drive genes for a human VEGF isoform, VEGF165, and LacZ. A mouse myocardial ischemic model was generated by ligation of the anterior descending coronary artery. Approx. 1011 copies of the AAV-VEGF vector mixed with 1010 copies of AAV-LacZ were injected to one site of normal myocardium and a total of 1011 copies of AAV-VEGF were injected to multiple sites of myocardium around the ischemic region. LacZ gene expression was obsd. up to 3 mo after the vector inoculation. After AAV-VEGF inoculation, neoangiogenesis was obsd. in the ischemic heart model but not in normal heart tissue. An inflammatory-cell infiltration was not obsd. in the AAV-VEGF- and AAV-LacZ-inoculated hearts, and angioma-like structure was not obsd. These results indicated that injection of the AAV vector directly to myocardium could mediate efficient gene transfer and transgene expression and that VEGF gene delivered by AAV vector can induce angiogenesis in ischemic myocardium.

L9 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Guo, Kun; Pagnoni, Marco F.; Clark, Kenneth L.; Ivashchenko, Yuri D.
 TI Human protein kinase Akt3 nucleic acids, polypeptides, and biological functions and applications
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2

AB The present invention relates to human Akt3 proteins and polypeptides. The 3rd isoform of AH/PH domain-contg. serine/threonine kinase (Akt3) was cloned from a human cDNA library and shown to comprise a 465-amino acid protein that is ubiquitously expressed with the highest level of expression obsd. in the heart. Akt3 protein possesses Akt activity and inhibits apoptotic stimulating kinase 1 (ASK1)-induced cell death in HEK293 cells. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors contg. them and to their therapeutic uses, in particular for **gene therapy**. Expression of Akt3 inhibits cell death assocd. with hypoxia, apoptosis or necrosis.

L9 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Leiden, Jeffrey M.; Svensson, Eric
 TI Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant **adeno-associated virus** vectors
 SO PCT Int. Appl., 20 pp.
 CODEN: PIXXD2

AB Recombinant **adeno-assocd. virus** (rAAV) vectors are used to transduce cardiomyocytes in vivo by infusing the rAAV into a **coronary artery** or **coronary sinus**. RAAV infection is not assocd. with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.

L9 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Hammond, H. Kirk
 TI Gene transfer-mediated angiogenesis therapy and techniques for intravascular gene delivery
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2

AB Transgene-inserted vectors are effectively used for in vivo **gene therapy** for peripheral vascular **disease, heart disease** and other conditions, by direct injection of the vector into arteries supplying the tissue to be targeted, preferably in combination with a vasoactive agent that is infused into the artery prior to or coincident with delivery of the vector.

L9 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Woolf, Tod M.
 TI Novel methods of stabilizing mRNA
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2

AB The invention describes novel methods of altering eukaryotic mRNA, resulting in its stabilization against nucleases and enabling it to transiently express proteins of interest in a cell. Stabilization of the mRNA of the invention can be achieved by end blocking modifications, sequence modifications, and/or chem. modifications. In one aspect, the invention pertains to modified mRNA mols. encoding therapeutically relevant proteins and the possible use of said mRNA in sense RNA therapy.

L9 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Hammond, H. Kirk; Kelly, Tamsin L.
 TI Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes

- SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
- AB Methods are provided for treating patients with congestive heart failure (including dilated cardiomyopathy and congestive heart failure assocd. with severe **coronary artery** disease), and for preventing or alleviating deleterious ventricular remodeling after myocardial infarction. The preferred methods of the present invention involve in vivo delivery of genes encoding angiogenic proteins or peptides to the myocardium by direct injection of a vector contg. the gene into a blood vessel supplying the heart. Preferred angiogenic factors include members of the fibroblast growth factor family, the vascular endothelial growth factor family, the platelet-derived growth factor family, and the insulin-like growth factor family. Thus, a helper-independent replication-defective human adenovirus 5 system is used effectively to transfect a large percentage of myocardial cells in vivo by a single intracoronary injection. Such a delivery technique is used to effectively target vectors to the myocardium of a large mammal heart, using the myosin light chain 2 or myosin heavy chain promoters specific for cardiac myocytes. Transient adenovirus-mediated gene transfer is therapeutically adequate for treating cardiovascular conditions. Within 14 days after gene transfer of fibroblast growth factor 5 (FGF5) into the myocardium, blood flow to the ischemic bed had increased 2-fold and the effect persisted for .gtoreq.12 wk. Wall thickening also increased within 2 wks after gene transfer and persisted for .gtoreq.12 wk.
- L9 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hammond, H. Kirk; Insel, Paul A.; Ping, Peipei; Post, Steven R.; Gao, Meihua
TI **Gene therapy** for congestive heart failure using genes for .beta.-adrenoceptors to increase responsiveness to .beta.-adrenergic agonists
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
- AB Cardiac function is improved in the treatment of congestive heart failure by introduction of a gene that increase .beta.-adrenergic responsiveness within the myocardium. The gene may be any of several involved in the .beta.-adrenoceptor signal transduction chain and may include the receptor itself, a G protein receptor kinase inhibitor, or an adenyl cyclase. The preferred gene is one for a cardiac isoenzyme of adenylate cyclase. Studies in a pig model of congestive heart demonstrated a role for adenyl cyclase in cardiac function and in congestive heart failure. A .beta.-adrenoceptor and G-protein receptor kinase were also shown to be involved in this model. A method for rapid screening of constructs for efficiency of gene transfer using rat ventricular myocytes is described. Successful transfer of genes from adenoviral vectors into the myocardium is demonstrated in a swine heart failure model.
- L9 ANSWER 18 OF 19 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AU Su, Hua; Arakawa-Hoyt, Janice; Kan, Yuet Wai (1)
TI Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model.
SO Proceedings of the National Academy of Sciences of the United States of America, (July 9, 2002) Vol. 99, No. 14, pp. 9480-9485.
<http://www.pnas.org>. print.
ISSN: 0027-8424.
- AB Intramyocardial injection of genes encoding angiogenic factors could provide a useful approach for the treatment of ischemic **heart disease**. However, uncontrolled expression of angiogenic factors in vivo may cause some unwanted side effects, such as hemangioma formation, retinopathy, and arthritis. It may also induce occult tumor growth and atherosclerotic plaque progression. Because hypoxia-inducible factor 1 is up-regulated in a variety of hypoxic conditions and it regulates gene expression by binding to a cis-acting hypoxia-responsive element (HRE), we propose to use HRE, found in the 3' end of the erythropoietin gene to

control gene expression in ischemic myocardium. A concatemer of nine copies of the consensus sequence of HRE isolated from the erythropoietin enhancer was used to mediate hypoxia induction. We constructed two adeno-associated viral vectors in which LacZ and vascular endothelial growth factor (VEGF) expressions were controlled by this HRE concatemer and a minimal simian virus 40 promoter. Both LacZ and VEGF expression were induced by hypoxia and/or anoxia in several cell lines transduced with these vectors. The functions of these vectors in ischemic myocardium were tested by injecting them into normal and ischemic mouse myocardium created by occlusion of the left anterior descending **coronary artery**. The expression of LacZ gene was induced eight times and of VEGF 20 times in ischemic myocardium compared with normal myocardium after the viral vector transduction. Hence, HRE is a good candidate for the control of angiogenic factor gene expression in ischemic myocardium.

L9 ANSWER 19 OF 19 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AU Melo, Luis Gabriel (1); Agrawal, Reitu A. (1); Zhang, Lunan (1); Rezvani, Mojgan (1); Mangi, Abeel A. (1); Dell'Acqua, Giorgio (1); Yet, Shaw-Fang (1); Perrella, Mark A.; Dzau, Victor J.
 TI Intramyocardial delivery of heme oxygenase-1 gene by **adeno-associated virus** provides long-term protection from ischemia/reperfusion injury.
 SO Circulation, (October 23, 2001) Vol. 104, No. 17 Supplement, pp. II.35.
<http://circ.ahajournals.org/>. print.
 Meeting Info.: Scientific Sessions 2001 of the American Heart Association
 Anaheim, California, USA November 11-14, 2001
 ISSN: 0009-7322.

=> d bib 3-9 12-17 19

L9 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:946119 CAPLUS
 DN 138:19497
 TI Methods of treating **cardiac disorders**
 IN Dzau, Victor; Melo, Luis G.; Perrella, Mark A.; Agrawal, Reitu
 PA The Brigham and Women's Hospital, Inc., USA
 SO PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098432	A1	20021212	WO 2002-US17628	20020603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003022870	A1	20030130	US 2002-161921	20020603
PRAI	US 2001-295229P	P	20010601		
RE.CNT	5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L9 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:868781 CAPLUS
 DN 137:363071
 TI Techniques and compositions for treating **cardiovascular**

disease by in vivo angiogenic polypeptide-encoding gene delivery

IN Hammond, H. Kirk
PA The Regents of the University of California, USA
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089856	A1	20021114	WO 2002-US13990	20020503
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 9947541	A1	19991125	AU 1999-47541	19990910
	US 2003148968	A1	20030807	US 2001-847936	20010503
PRAI	US 2001-847936	A	20010503		
	US 1995-396207	B2	19950228		
	US 1995-485472	A2	19950607		
	AU 1996-50287	A3	19960227		
	US 1997-852779	B1	19970506		
	US 1997-722271	A2	19971229		
	US 1998-21773	B2	19980211		
	US 1998-68102	B2	19980430		
	US 1998-132167	A1	19980810		
	WO 1999-US2702	A2	19990209		
	US 1999-435156	B2	19991105		
	US 2000-609080	B2	20000630		
	WO 2000-US30345	A2	20001103		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:716105 CAPLUS
DN 137:237709
TI Vectors, compositions and methods for treating a vascular disorder
IN Wu, Kenneth K.
PA Board of Regents, the University of Texas System, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072115	A2	20020919	WO 2002-US7164	20020308
	WO 2002072115	A3	20021107		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002168739	A1	20021114	US 2002-94210	20020308

PRAI US 2001-274866P P 20010309

L9 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:575750 CAPLUS
DN 137:145549
TI **Gene therapy** for congestive heart failure
IN Hammond, H. Krik; Insel, Paul A.; Ping, Peipei; Post, Steven R.; Gao, Meihua
PA USA
SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 472,667.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002103147	A1	20020801	US 2000-750240	20001226
	WO 9810085	A2	19980312	WO 1997-US15610	19970905
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 9940945	A2	19990819	WO 1999-US2702	19990209
	WO 9940945	A3	19990930		
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9947541	A1	19991125	AU 1999-47541	19990910
PRAI	WO 1997-US15610	A	19970905		
	WO 1999-US2702	A	19990209		
	US 1999-472667	A2	19991227		
	AU 1996-50287	A3	19960227		
	US 1996-708661	A2	19960905		
	US 1997-48933P	P	19970616		
	US 1998-21773	A	19980211		

L9 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:31287 CAPLUS
DN 136:74573
TI Dual recombinant **gene therapy** compositions and methods of use
IN Gao, Mei Hua
PA Collateral Therapeutics, Inc., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002148	A2	20020110	WO 2001-US21059	20010628
	WO 2002002148	A3	20021017		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1294407 A2 20030326 EP 2001-984094 20010628
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRAI US 2000-607766 A2 20000630
 US 2001-826291 A2 20010403
 WO 2001-US21059 W 20010628

L9 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:923851 CAPLUS
 DN 136:68690
 TI CD154 variants
 IN Hsu, Yen-Ming; Garber, Ellen
 PA Biogen, Inc., USA
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001096397	A2	20011220	WO 2001-US18517	20010608
WO 2001096397	A3	20020502		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1294874 A2 20030326 EP 2001-946167 20010608 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR PRAI US 2000-210657P P 20000609 WO 2001-US18517 W 20010608				

L9 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:693508 CAPLUS
 DN 135:269286
 TI Human protein kinase Akt3 and cDNAs encoding it and the use of the enzyme
 in treatment of hypoxia, apoptosis or necrosis
 IN Guo, Kun; Pagnoni, Marco F.; Clark, Kenneth L.; Ivashchenko, Yuri D.
 PA Aventis Pharmaceuticals Products Inc., USA
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001068850	A2	20010920	WO 2001-US7663	20010309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				

YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003100049 A1 20030529 US 2000-526043 20000314
PRAI US 2000-526043 A 20000314
US 1999-125108P P 19990319

L9 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:688350 CAPLUS

DN 133:263211

TI Human protein kinase Akt3 nucleic acids, polypeptides, and biological functions and applications

IN Guo, Kun; Pagnoni, Marco F.; Clark, Kenneth L.; Ivashchenko, Yuri D.

PA Aventis Pharmaceuticals Products Inc., USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056866	A2	20000928	WO 2000-US6574	20000314
	WO 2000056866	A3	20010215		
	WO 2000056866	C2	20020829		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2343074	AA	20000928	CA 2000-2343074	20000314
	EP 1144600	A2	20011017	EP 2000-917899	20000314
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO			
	BR 2000009170	A	20020430	BR 2000-9170	20000314
	JP 2002539781	T2	20021126	JP 2000-606725	20000314
	NO 2001004537	A	20011031	NO 2001-4537	20010918
PRAI	US 1999-125108P	P	19990319		
	WO 2000-US6574	W	20000314		

L9 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:456818 CAPLUS

DN 133:53712

TI Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant **adeno-associated virus** vectors

IN Leiden, Jeffrey M.; Svensson, Eric

PA Arch Development Corp., USA

SO PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038518	A1	20000706	WO 1999-US31093	19991228
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,			

BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2356551 AA 20000706 CA 1999-2356551 19991228
 EP 1139751 A1 20011010 EP 1999-967703 19991228
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002533359 T2 20021008 JP 2000-590483 19991228
 AU 763049 B2 20030710 AU 2000-23942 19991228
 PRAI US 1998-113923P P 19981228
 WO 1999-US31093 W 19991228
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:529050 CAPLUS

DN 131:175050

TI Gene transfer-mediated angiogenesis therapy and techniques for
 intravascular gene delivery

IN Hammond, H. Kirk

PA The Regents of the University of California, USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940945	A2	19990819	WO 1999-US2702	19990209
	WO 9940945	A3	19990930		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2320302	AA	19990819	CA 1999-2320302	19990209
	AU 9926637	A1	19990830	AU 1999-26637	19990209
	EP 1053025	A2	20001122	EP 1999-906814	19990209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002502885	T2	20020129	JP 2000-531196	19990209
	ZA 9901102	A	20000331	ZA 1999-1102	19990211
	AU 9947541	A1	19991125	AU 1999-47541	19990910
	US 2002103147	A1	20020801	US 2000-750240	20001226
	US 2003148968	A1	20030807	US 2001-847936	20010503
PRAI	US 1998-21773	A	19980211		
	US 1995-396207	B2	19950228		
	US 1995-485472	A2	19950607		
	AU 1996-50287	A3	19960227		
	US 1997-852779	B1	19970506		
	WO 1997-US15610	A	19970905		
	US 1997-722271	A2	19971229		
	US 1998-68102	B2	19980430		
	US 1998-132167	A1	19980810		
	WO 1999-US2702	W	19990209		
	US 1999-435156	B2	19991105		
	US 1999-472667	A2	19991227		
	US 2000-609080	B2	20000630		
	WO 2000-US30345	A2	20001103		

L9 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:220070 CAPLUS
 DN 130:234329
 TI Novel methods of stabilizing mRNA
 IN Woolf, Tod M.
 PA Sequitur, Inc., USA
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9914346	A2	19990325	WO 1998-US19492	19980918
	WO 9914346	A3	19990527		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2304982	AA	19990325	CA 1998-2304982	19980918
	AU 9893193	A1	19990405	AU 1998-93193	19980918
	EP 1021549	A2	20000726	EP 1998-946108	19980918
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002508299	T2	20020319	JP 2000-511884	19980918
PRAI	US 1997-59371P	P	19970919		
	WO 1998-US19492	W	19980918		

L9 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:744977 CAPLUS
 DN 130:10634
 TI Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
 IN Hammond, H. Kirk; Kelly, Tamsin L.
 PA The Regents of the University of California, USA
 SO PCT Int. Appl., 87 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850079	A2	19981112	WO 1998-US8848	19980430
	WO 9850079	A3	19990204		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9871735	A1	19981127	AU 1998-71735	19980430
	EP 980428	A2	20000223	EP 1998-918904	19980430
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002515065	T2	20020521	JP 1998-548243	19980430
	AU 9947541	A1	19991125	AU 1999-47541	19990910
PRAI	US 1997-852779	A	19970506		

US 1997-86239P A 19970506
 AU 1996-50287 A3 19960227
 WO 1998-US8848 W 19980430

L9 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:176033 CAPLUS

DN 128:242638

TI **Gene therapy** for congestive heart failure using genes
 for .beta.-adrenoceptors to increase responsiveness to .beta.-adrenergic
 agonists

IN Hammond, H. Kirk; Insel, Paul A.; Ping, Peipei; Post, Steven R.; Gao,
 Meihua

PA Regents of the University of California, USA; Collateral Therapeutics;
 Hammond, H. Kirk; Insel, Paul A.; Ping, Peipei; Post, Steven R.; Gao,
 Meihua

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9810085	A2	19980312	WO 1997-US15610	19970905
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK,				
	EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US,				
	UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
	AU 9742519	A1	19980326	AU 1997-42519	19970905
	AU 741931	B2	20011213		
	ZA 9708019	A	19981111	ZA 1997-8019	19970905
	EP 934422	A2	19990811	EP 1997-940830	19970905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	CN 1234835	A	19991110	CN 1997-197695	19970905
	JP 2002514908	T2	20020521	JP 1998-512915	19970905
	US 6306830	B1	20011023	US 1998-8097	19980116
	AU 9947541	A1	19991125	AU 1999-47541	19990910
	US 2002103147	A1	20020801	US 2000-750240	20001226
PRAI	US 1996-708661	A2	19960905		
	US 1997-48933P	P	19970616		
	AU 1996-50287	A3	19960227		
	WO 1997-US15610	W	19970905		
	WO 1999-US2702	A	19990209		
	US 1999-472667	A2	19991227		

=>

=> d bib ab 1-3 113

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:456818 CAPLUS
DN 133:53712
TI Efficient and stable in vivo gene transfer to cardiomyocytes using
recombinant **adeno-associated virus** vectors
IN Leiden, Jeffrey M.; Svensson, Eric
PA Arch Development Corp., USA
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038518	A1	20000706	WO 1999-US31093	19991228
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2356551	AA	20000706	CA 1999-2356551	19991228
	EP 1139751	A1	20011010	EP 1999-967703	19991228
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002533359	T2	20021008	JP 2000-590483	19991228
	AU 763049	B2	20030710	AU 2000-23942	19991228
PRAI	US 1998-113923P	P	19981228		
	WO 1999-US31093	W	19991228		
AB	Recombinant adeno-assocd. virus (rAAV) vectors are used to transduce cardiomyocytes in vivo by infusing the rAAV into a coronary artery or coronary sinus. RAAV infection is not assocd. with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.				
RE.CNT 4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:529050 CAPLUS
DN 131:175050
TI Gene transfer-mediated angiogenesis therapy and techniques for
intravascular gene delivery
IN Hammond, H. Kirk
PA The Regents of the University of California, USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940945	A2	19990819	WO 1999-US2702	19990209
	WO 9940945	A3	19990930		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			

DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2320302	AA	19990819	CA 1999-2320302	19990209
AU 9926637	A1	19990830	AU 1999-26637	19990209
EP 1053025	A2	20001122	EP 1999-906814	19990209

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2002502885	T2	20020129	JP 2000-531196	19990209
ZA 9901102	A	20000331	ZA 1999-1102	19990211
AU 9947541	A1	19991125	AU 1999-47541	19990910
US 2002103147	A1	20020801	US 2000-750240	20001226
US 2003148968	A1	20030807	US 2001-847936	20010503

PRAI US 1998-21773 A 19980211
 US 1995-396207 B2 19950228
 US 1995-485472 A2 19950607
 AU 1996-50287 A3 19960227
 US 1997-852779 B1 19970506
 WO 1997-US15610 A 19970905
 US 1997-722271 A2 19971229
 US 1998-68102 B2 19980430
 US 1998-132167 A1 19980810
 WO 1999-US2702 W 19990209
 US 1999-435156 B2 19991105
 US 1999-472667 A2 19991227
 US 2000-609080 B2 20000630
 WO 2000-US30345 A2 20001103

AB Transgene-inserted vectors are effectively used for in vivo gene therapy for peripheral vascular **disease**, **heart disease** and other conditions, by direct injection of the vector into arteries supplying the tissue to be targeted, preferably in combination with a vasoactive agent that is **infused** into the **artery** prior to or coincident with delivery of the vector.

L13 ANSWER 3 OF 3 MEDLINE on STN DUPLICATE 1

AN 97116282 MEDLINE

DN 97116282 PubMed ID: 8957370

TI Long-term gene transfer in porcine myocardium after coronary infusion of an **adeno-associated virus** vector.

AU Kaplitt M G; Xiao X; Samulski R J; Li J; Ojamaa K; Klein I L; Makimura H; Kaplitt M J; Strumpf R K; Diethrich E B

CS Department of Surgery, New York Hospital-Cornell University Medical College, New York, USA.

SO ANNALS OF THORACIC SURGERY, (1996 Dec) 62 (6) 1669-76.
 Journal code: 15030100R. ISSN: 0003-4975.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199701

ED Entered STN: 19970128

Last Updated on STN: 19970128

Entered Medline: 19970109

AB BACKGROUND: Viral vector-mediated gene transfer into the heart represents a potentially powerful tool for studying both cardiac physiology as well as gene therapy of **cardiac disease**. We report here the use of a defective viral vector, which expresses no viral gene products, for gene transfer into the mammalian heart. Previous studies have used recombinant viral vectors, which retained viral genes and

yielded mostly short-term expression, often with significant inflammation.

METHODS: An **adeno-associated virus** vector was used that contains no viral genes and is completely free of contaminating helper viruses. The **adeno-associated virus** vector was applied to rat hearts by direct intramuscular injection; **adeno-associated virus** was also infused into pig hearts in vivo via percutaneous intraarterial infusion into the coronary vasculature using routine catheterization techniques.

RESULTS: Gene transfer into rat heart yielded no apparent inflammation, and expression was observed for at least 2 months after injection.

Infusion into pig circumflex coronary **arteries** resulted in successful transfer and expression of the reporter gene in cardiac myocytes without apparent toxicity or inflammation; gene expression was observed for at least 6 months after infusion. **CONCLUSIONS:** We report the use of **adeno-associated virus** vectors in the cardiovascular system as well as successful myocardial gene transfer after percutaneous coronary **artery infusion** of viral vectors in a large, clinically relevant mammalian model. These results suggest that safe and stable gene transfer can be achieved in the heart using standard outpatient cardiac catheterization techniques.

=>

=> d au ti so 1-33 18

- L8 ANSWER 1 OF 33 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AU Tsui T Y (Reprint); Wu X B; Lau C K; Ho D W Y; Xu T; Siu Y T; Fan S T
TI Prevention of chronic deterioration of heart allograft by recombinant
adeno-associated virus-mediated heme
oxygenase-1 gene transfer
SO CIRCULATION, (27 MAY 2003) Vol. 107, No. 20, pp. 2623-2629.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA
19106-3621 USA.
ISSN: 0009-7322.
- L8 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AU Squadrito, Francesco; Deodato, Barbara; Squadrito, Giovanni; Seminara,
Paolo; Passaniti, Maria; Venuti, Francesco S.; Giacca, Mauro; Minutoli,
Letteria; Adamo, Elena B.; Bellomo, Maria; Marini, Rolando; Galeano,
Mariarosaria; Marini, Herbert; Altavilla, Domenica
TI Gene Transfer of I.kappa.B.alpha. Limits Infarct Size in a Mouse Model of
Myocardial Ischemia-Reperfusion Injury
SO Laboratory Investigation (2003), 83(8), 1097-1104
CODEN: LAINAW; ISSN: 0023-6837
- L8 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
IN Dzau, Victor; Melo, Luis G.; Perrella, Mark A.; Agrawal, Reitu
TI Methods of treating cardiac disorders
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
- L8 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hammond, H. Kirk
TI Techniques and compositions for treating cardiovascular disease by in vivo
angiogenic polypeptide-encoding gene delivery
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
- L8 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
IN Lahtinen, Mika; Laukanen, Mikko; Yla-Herttuala, Seppo; Leppanen,
Olli-Pekka
TI Medical implant device comprising a nucleic acid encoding superoxide
dismutase to inhibit connective tissue hyperplasia
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
- L8 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
IN Wu, Kenneth K.
TI Vectors, compositions and methods for treating a vascular disorder
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
- L8 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
IN Gao, Mei Hua
TI Dual recombinant **gene therapy** compositions and methods
of use
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
- L8 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hammond, H. Krik; Insel, Paul A.; Ping, Peipei; Post, Steven R.; Gao,
Meihua
TI **Gene therapy** for congestive heart failure
SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 472,667.
CODEN: USXXCO
- L8 ANSWER 9 OF 33 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

AU Su, Hua; Arakawa-Hoyt, Janice; Kan, Yuet Wai (1)
 TI Adeno-associated viral vector-mediated hypoxia response element-regulated
 gene expression in mouse ischemic heart model.
 SO Proceedings of the National Academy of Sciences of the United States of
 America, (July 9, 2002) Vol. 99, No. 14, pp. 9480-9485.
<http://www.pnas.org>. print.
 ISSN: 0027-8424.

L8 ANSWER 10 OF 33 MEDLINE on STN DUPLICATE 1
 AU Melo Luis G; Agrawal Reitu; Zhang Lunan; Rezvani Mojgan; Mangi Abeel A;
 Ehsan Afshin; Griesse Daniel P; Dell'Acqua Giorgio; Mann Michael J; Oyama
 Junichi; Yet Shaw-Fang; Layne Matthew D; Perrella Mark A; Dzau Victor J
 TI **Gene therapy** strategy for long-term myocardial
 protection using **adeno-associated virus**
 -mediated delivery of heme oxygenase gene.
 SO CIRCULATION, (2002 Feb 5) 105 (5) 602-7.
 Journal code: 0147763. ISSN: 1524-4539.

L8 ANSWER 11 OF 33 MEDLINE on STN DUPLICATE 2
 AU Asfour B; Baba H A; Scheld H H; Hruban R H; Hammel D; Byrne B J
 TI Uniform long-term gene expression using **adeno-associated**
virus (AAV) by ex vivo recirculation in rat-cardiac
 isografts.
 SO THORACIC AND CARDIOVASCULAR SURGEON, (2002 Dec) 50 (6) 347-50.
 Journal code: 7903387. ISSN: 0171-6425.

L8 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Hsu, Yen-Ming; Garber, Ellen
 TI CD154 variants
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2

L8 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Guo, Kun; Pagnoni, Marco F.; Clark, Kenneth L.; Ivashchenko, Yuri D.
 TI Human protein kinase Akt3 and cDNAs encoding it and the use of the enzyme
 in treatment of hypoxia, apoptosis or necrosis
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2

L8 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Yen, Frances; Erickson, Mary Ruth; Fruebis, Joachim; Bihain, Bernard
 TI Methods of screening for compounds that modulate the LSR (lipolysis
 stimulated receptor)-leptin interaction and their use in the prevention
 and treatment of obesity-related diseases
 SO PCT Int. Appl., 247 pp.
 CODEN: PIXXD2

L8 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Zoldhelyi, Pierre; Willerson, James T.; Cunningham, Janet
 TI Recombinant **adeno-associated virus** (rAAV)
 expressing proteins involved in preventing cell proliferation, thrombosis,
 and/or cell migration in a vascular graft
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2

L8 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Dichek, David A.; Schneider, Darren; Vassalli, Giuseppe
 TI Methods for screening agents for the treatment of atherosclerosis in
 non-human mammalian model of atherosclerosis
 SO U.S. Pat. Appl. Publ., 39 pp.
 CODEN: USXXCO

L8 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 AU Chen, Z.; Lu, L.; Li, J.; Li, W.; Fung, J. J.; Xiao, X.; Qian, S.

- TI Transfection with genes encoding CTLA4Ig mediated by adenoassociated virus vectors prolongs survival of heart allografts
 SO Transplantation Proceedings (2001), 33(1-2), 604
 CODEN: TRPPA8; ISSN: 0041-1345
- L8 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 AU Liang, Hongli; Zhu, Hongsheng; Zhang, Jingying; Huang, Zhongyao; Chen, Shishu
 TI Inhibition of vascular smooth cell proliferation with transfer of wild-type p53 gene using vector based on **adeno-associated virus** plasmid
 SO Zhejiang Daxue Xuebao, Yixueban (2001), 30(1), 1-5
 CODEN: ZDXYA9; ISSN: 1008-9292
- L8 ANSWER 19 OF 33 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AU Agrawal, Reitu S. (1); Muangman, Suphichaya; Melo, Luis G.; Layne, Matthew D.; Lopez-Illasaca, Marco; Perrella, Mark A.; Lee, Richard T.; Zhang, Lunan; Dzau, Victor J.
 TI Localized delivery of **adeno-associated virus** vector expressing human extracellular superoxide dismutase gene confers long term protection against ischemia-reperfusion injury to the rat heart.
 SO Circulation, (October 23, 2001) Vol. 104, No. 17 Supplement, pp. II.36.
<http://circ.ahajournals.org/>. print.
 Meeting Info.: Scientific Sessions 2001 of the American Heart Association Anaheim, California, USA November 11-14, 2001
 ISSN: 0009-7322.
- L8 ANSWER 20 OF 33 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AU Melo, Luis Gabriel (1); Agrawal, Reitu A. (1); Zhang, Lunan (1); Rezvani, Mojgan (1); Mangi, Abeel A. (1); Dell'Acqua, Giorgio (1); Yet, Shaw-Fang (1); Perrella, Mark A.; Dzau, Victor J.
 TI Intramyocardial delivery of heme oxygenase-1 gene by **adeno-associated virus** provides long-term protection from ischemia/reperfusion injury.
 SO Circulation, (October 23, 2001) Vol. 104, No. 17 Supplement, pp. II.35.
<http://circ.ahajournals.org/>. print.
 Meeting Info.: Scientific Sessions 2001 of the American Heart Association Anaheim, California, USA November 11-14, 2001
 ISSN: 0009-7322.
- L8 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Guo, Kun; Pagnoni, Marco F.; Clark, Kenneth L.; Ivashchenko, Yuri D.
 TI Human protein kinase Akt3 nucleic acids, polypeptides, and biological functions and applications
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
- L8 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Leiden, Jeffrey M.; Svensson, Eric
 TI Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant **adeno-associated virus** vectors
 SO PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
- L8 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 AU Su, Hua; Lu, Ronghua; Kan, Yuet Wai
 TI Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart
 SO Proceedings of the National Academy of Sciences of the United States of America (2000), 97(25), 13801-13806
 CODEN: PNASA6; ISSN: 0027-8424
- L8 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Hammond, H. Kirk

TI Gene transfer-mediated angiogenesis therapy and techniques for
 intravascular gene delivery
 SO PCT Int. Appl., 46 pp.
 CODEN: PIXXD2

L8 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Woolf, Tod M.
 TI Novel methods of stabilizing mRNA
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2

L8 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Schrader, Juergen
 TI Transfection system, its production and use in somatic **gene
 therapy**
 SO Ger. Offen., 10 pp.
 CODEN: GWXXBX

L8 ANSWER 27 OF 33 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AU Sendler, U. (1); Valina, C. (1); Sack, P. (1); Laugwitz, K. L. (1);
 Kleinschmidt, J.; Neumann, F. J. (1)
 TI Gene transfer in **coronary arteries** of a porcine animal
 model: Comparison of three-vector systems.
 SO European Heart Journal, (Aug., 1999) Vol. 20, No. ABSTR. SUPPL., pp. 412.
 Meeting Info.: XXIst Congress of the European Society of Cardiology
 Barcelona, Spain August 28-September 1, 1999 European Society of
 Cardiology
 . ISSN: 0195-668X.

L8 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Jarvis, Thale; Matulic-Adamic, Jasenka; Reynolds, Mark; Kisich, Kevin;
 Bellon, Laurent; Parry, Tom; Beigelman, Leonid; McSwiggen, James A.;
 Karpeisky, Alexander; Burgin, Alex; Thompson, James; Workman, Christopher
 T.; Beaudry, Amber; Sweedler, David
 TI Enzymic ribozyme treatment of diseases or cancers related to expression of
 c-raf gene
 SO PCT Int. Appl., 259 pp.
 CODEN: PIXXD2

L8 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Hammond, H. Kirk; Kelly, Tamsin L.
 TI Techniques and compositions for treating heart failure and ventricular
 remodeling by in vivo delivery of angiogenic transgenes
 SO PCT Int. Appl., 87 pp.
 CODEN: PIXXD2

L8 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Hammond, H. Kirk; Insel, Paul A.; Ping, Peipei; Post, Steven R.; Gao,
 Meihua
 TI **Gene therapy** for congestive heart failure using genes
 for .beta.-adrenoceptors to increase responsiveness to .beta.-adrenergic
 agonists
 SO PCT Int. Appl., 114 pp.
 CODEN: PIXXD2

L8 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Goldenberg, Tsvi; Tritz, Richard
 TI Ribozyme therapy for the inhibition of restenosis
 SO U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 207,649, abandoned.
 CODEN: USXXAM

L8 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
 IN Goldenberg, Tsvi; Tritz, Richard
 TI Ribozyme therapy for treatment and/or prevention of restenosis

SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

L8 ANSWER 33 OF 33 MEDLINE on STN DUPLICATE 3
AU Kaplitt M G; Xiao X; Samulski R J; Li J; Ojamaa K; Klein I L; Makimura H;
Kaplitt M J; Strumpf R K; Diethrich E B
TI Long-term gene transfer in porcine myocardium after coronary infusion of
an **adeno-associated virus** vector.
SO ANNALS OF THORACIC SURGERY, (1996 Dec) 62 (6) 1669-76.
Journal code: 15030100R. ISSN: 0003-4975.

=> d bib 28 32 18

L8 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:747594 CAPLUS
DN 130:22238
TI Enzymic ribozyme treatment of diseases or cancers related to expression of
c-raf gene
IN Jarvis, Thale; Matulic-Adamic, Jasenka; Reynolds, Mark; Kisich, Kevin;
Bellon, Laurent; Parry, Tom; Beigelman, Leonid; McSwiggen, James A.;
Karpeisky, Alexander; Burgin, Alex; Thompson, James; Workman, Christopher
T.; Beaudry, Amber; Sweedler, David
PA Ribozyme Pharmaceuticals, Inc., USA; et al.
SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 52

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850530	A2	19981112	WO 1998-US9249	19980505
	WO 9850530	A3	19990729		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9851819	A1	19980611	AU 1998-51819	19980112
	AU 729657	B2	20010208		
	AU 9872905	A1	19981127	AU 1998-72905	19980505
	AU 749561	B2	20020627		
	EP 980424	A2	20000223	EP 1998-920299	19980505
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2001525667	T2	20011211	JP 1998-548448	19980505
	EP 1321521	A1	20030625	EP 2003-2270	19980505
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
	US 6054576	A	20000425	US 1998-164964	19981001
	US 6162909	A	20001219	US 1999-326154	19990604
	AU 9939188	A1	19990916	AU 1999-39188	19990713
	US 6303773	B1	20011016	US 2000-644962	20000823
	US 2002028919	A1	20020307	US 2001-960192	20010921
	US 6489465	B2	20021203		
	US 2002103366	A1	20020801	US 2001-957841	20010921
	US 2003125291	A1	20030703	US 2002-277263	20021022
PRAI	US 1997-46059P	P	19970509		
	US 1997-49002P	P	19970609		
	US 1997-51718P	P	19970703		
	US 1997-56808P	P	19970822		

US 1997-61321P	P	19971002
US 1997-61324P	P	19971002
US 1997-64866P	P	19971105
US 1997-68212P	P	19971219
AU 1995-26422	A3	19950518
US 1996-623891	A	19960325
WO 1998-US9249	W	19980505
US 1998-135964	A1	19980818
US 1998-164964	A1	19981001
EP 1998-920299	A3	19981112
US 1999-326154	A1	19990604
US 2000-644962	A1	20000823
US 2001-960192	A1	20010921

OS MARPAT 130:22238

L8 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:299376 CAPLUS

DN 126:272370

TI Ribozyme therapy for treatment and/or prevention of restenosis

IN Goldenberg, Tsvi; Tritz, Richard

PA Immusol, Inc., USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9710334	A2	19970320	WO 1996-US14838	19960912
	WO 9710334	A3	19970605		
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5834440	A	19981110	US 1995-527060	19950912
	EP 850301	A2	19980701	EP 1996-932236	19960912
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11514855	T2	19991221	JP 1996-512173	19960912
PRAI	US 1995-527060		19950912		
	US 1994-207649		19940307		
	WO 1996-US14838		19960912		

=>